Factor XIII transglutaminase supports hematogenous tumor cell metastasis through a mechanism dependent on natural killer cell function

Journal of Thrombosis and Haemostasis

Volumn 6, Issue 5, 2008, Pages 812-819

  Palumbo, Joe S ^a   Barney, K A ^a   Blevins, E A ^a   Shaw, M A ^a   Mishra, A ^a   Flick, M J ^a   Kombrinck, K W ^a   Talmage, K E ^a   Souri, M ^a   Ichinose, A ^a   Degen, J L ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b YAMAGATA UNIVERSITY   (Japan)

Author keywords

Coagulation; Hemostatic factors; Immune surveillance; Malignancy

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8A; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE TARGETING; HEMOSTASIS; IMMUNOCOMPETENCE; IMMUNOSURVEILLANCE; LYMPHOCYTE FUNCTION; MALE; METASTASIS; METASTASIS POTENTIAL; MICROMETASTASIS; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TUMOR CELL; TUMOR GROWTH; WILD TYPE;

ANIMALS; BLOOD PLATELETS; FACTOR XIII; FIBRIN; KILLER CELLS, NATURAL; MICE; MICE, KNOCKOUT; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; NEOPLASMS; THROMBOSIS; TRANSGLUTAMINASES; TUMOR ESCAPE;

EID: 42149137285     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2008.02938.x     Document Type: Article

References (24)

1. Ichinose A. Physiopathology and regulation of factor XIII. Thromb Haemost 2001; 86: 57-65.
2. Lorand L. Factor XIII and the clotting of fibrinogen: From basic research to medicine. J Thromb Haemost 2005; 3: 1337-48.
3. Dardik R, Loscalzo J, Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost 2006; 4: 19-25.
4. Adany R, Bardos H. Factor XIII subunit A as an intracellular transglutaminase. Cell Mol Life Sci 2003; 60: 1049-60.
5. Labat-Robert J. Fibronectin in malignancy. Semin Cancer Biol 2002; 12: 187-95.
6. Palumbo JS, Potter JM, Kaplan LS, Talmage K, Jackson DG, Degen JL. Spontaneous hematogenous and lymphatic metastasis, but not primary tumor growth or angiogenesis, is diminished in fibrinogen-deficient mice. Cancer Res 2002; 62: 6966-72.
7. Vairaktaris E, Vassiliou S, Yapijakis C, Spyridonidou S, Vylliotis A, Derka S, Nkenke E, Fourtounis G, Neukam FW, Patsouris E. Increased risk for oral cancer is associated with coagulation factor XIII but not with factor XII. Oncol Rep 2007; 18: 1537-43.
8. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Hu Z, Barney KA, Degen JL. Tumor cell-associated tissue factor and circulating hemostatic factors cooperate to increase metastatic potential through natural killer cell-dependent and -independent mechanisms. Blood 2007; 19.
9. Palumbo JS, Talmage KE, Massari JV, La Jeunesse CM, Flick MJ, Kombrinck KW, Jirouskova M, Degen JL. Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood. 2005; 105: 178-85.
10. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295-300.
11. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004; 104: 397-401.
12. Jain S, Zuka M, Liu J, Russell S, Dent J, Guerrero JA, Forsyth J, Maruszak B, Gartner TK, Felding-Habermann B, Ware J. Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proc Natl Acad Sci USA 2007; 104: 9024-8.
13. Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998; 101: 1372-8.
14. Tykocinski ML, Xiong N, Morrow DM. Platelet immunoregulatory factors. Stem Cells 1996; 14: 240-5.
15. Souri M, Koseki-Kuno S, Takeda N, Degen JL, Ichinose A. Administration of factor XIII B subunit increased plasma factor XIII A subunit levels in factor XIII B subunit knock-out mice. Int J Hematol 2008; 87: 60-8.
16. Lauer P, Metzner HJ, Zettlmeissl G, Li M, Smith AG, Lathe R, Dickneite G. Targeted inactivation of the mouse locus encoding coagulation factor XIII-A: Hemostatic abnormalities in mutant mice and characterization of the coagulation deficit. Thromb Haemost 2002; 88: 967-74.
17. Ballas ZK, Rasmussen W. Lymphokine-activated killer (LAK) cells. IV. Characterization of murine LAK effector subpopulations. J Immunol 1990; 144: 386-95.
18. Amirkhosravi A, Mousa SA, Amaya M, Blaydes S, Desai H, Meyer T, Francis JL. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost 2003; 90: 549-54.
19. Cho J, Mosher DF. Enhancement of thrombogenesis by plasma fibronectin cross-linked to fibrin and assembled in platelet thrombi. Blood 2006; 107: 3555-63.
20. Sane DC, Moser TL, Pippen AM, Parker CJ, Achyuthan KE, Greenberg CS. Vitronectin is a substrate for transglutaminases. Biochem Biophys Res Commun 1988; 157: 115-20.
21. Hada M, Kaminski M, Bockenstedt P, McDonagh J. Covalent crosslinking of von Willebrand factor to fibrin. Blood 1986; 68: 95-101.
22. Sakata Y, Aoki N. Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor. J Clin Invest 1980; 65: 290-7.
23. Dardik R, Loscalzo J, Eskaraev R, Inbal A. Molecular mechanisms underlying the proangiogenic effect of factor XIII. Arterioscler Thromb Vasc Biol 2005; 25: 526-32.
24. van Hinsbergh VW, Collen A, Koolwijk P. Role of fibrin matrix in angiogenesis. Ann N Y Acad Sci 2001; 936: 426-37.